標題: Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis - A nationwide cohort study
作者: Lin, Ting-Tse
Wu, Cho-Kai
Liao, Min-Tsun
Yang, Yao-Hsu
Chen, Pau-Chung
Yeih, Dong-Feng
Lin, Lian-Yu
分子醫學與生物工程研究所
Institute of Molecular Medicine and Bioengineering
公開日期: 7-Dec-2017
摘要: Background Rheumatoid arthritis (RA) is regarded as a high risk factor for myocardial infarction. Hypertension is a major modifiable risk factor contributing to increased risk of myocardial infarction (MI). Dual blood pressure (BP)-lowering and anti-inflammatory effect of renin-angiotensinsystem (RAS) inhibitors may possess protective effect from MI in RA population. However, treatment of hypertension with RAS inhibitors and MI in RA population remains unclear. Methods We investigated whether RAS blockade could decrease risk of incident MI in hypertensive patients with RA. We identified patients with RA and hypertension from the Registry for Catastrophic Illness, a nation-wide database encompassing almost all of the RA patients in Taiwan from 1995 to 2008. The primary endpoint was MI and the median duration of follow up was 2,986 days. Propensity score weighting and Cox proportional hazards regression models were used to estimate hazard ratios for MI. Results Among 27,335 subjects, 9.9% received angiotensin-converting enzyme inhibitors (ACEIs), 25.9% received angiotensin II receptor blockers (ARBs) and 20.0% received ACEIs or ARBs alternatively. The incidence of MI significantly decreased in patients treated with ACEIs (hazard ratio 0.707; 95% confidence interval 0.595 - 0.840), ARBs (0.641; 0.550 - 0.747) and ACEIs/ARBs (0.631; 0.539 - 0.739). The protective effect of ACEI or ARB therapy was significantly better in patients taking longer duration. The effect remained robust in subgroup analyses. Conclusions Therapy of ACEIs or ARBs is associated with a lower risk of MI among patients with RA. Hence, hypertension in patients with RA could comprise a compelling indication for RAS inhibitors.
URI: http://dx.doi.org/10.1371/journal.pone.0188720
http://hdl.handle.net/11536/144194
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0188720
期刊: PLOS ONE
Volume: 12
Issue: 12
起始頁: 0
結束頁: 0
Appears in Collections:Articles


Files in This Item:

  1. e2bf69f3a565e26b2de298da6ddd4048.pdf